surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 as Compared with Semaglutide for the Treatment of Obesity Continued Treatment With Tirzepatide for
Description
Those who tolerate and remain on 15 mg lose more than those who stay at 5 mg
My experience has been great and this is my second month
Sources Office of the Commissioner
If it is as effective as the injection, it could provide a more convenient option for many patients
Pivotal Phase 3 trials Trial SURMOUNT-1 (NEJM 2022) Population 2,539 adults, obesity, no diabetes
